These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30350286)

  • 1. [Toxicology of synthetic cannabinoids].
    Mouraouakkil Y; Mounir R; El Cadi MA; Lamsaouri J; Bousliman Y; ElJaoudi R
    Ann Biol Clin (Paris); 2024 Jun; 82(2):151-173. PubMed ID: 38721719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances: catalysing a shift in forensic science practice?
    Tettey J; Crean C
    Philos Trans R Soc Lond B Biol Sci; 2015 Aug; 370(1674):. PubMed ID: 26101290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel synthetic opioids - toxicological aspects and analysis.
    Tabarra I; Soares S; Rosado T; Gonçalves J; Luís Â; Malaca S; Barroso M; Keller T; Restolho J; Gallardo E
    Forensic Sci Res; 2019; 4(2):111-140. PubMed ID: 31304442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The search for the "next" euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning.
    Sharma KK; Hales TG; Rao VJ; NicDaeid N; McKenzie C
    Forensic Toxicol; 2019; 37(1):1-16. PubMed ID: 30636980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Educated Guesses and Other Ways to Address the Pharmacological Uncertainty of Designer Drugs: An Exploratory Study of Experimentation Through an Online Drug Forum.
    Berning M; Hardon A
    Contemp Drug Probl; 2016 Sep; 43(3):277-292. PubMed ID: 27721526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designer Benzodiazepines: Another Class of New Psychoactive Substances.
    Moosmann B; Auwärter V
    Handb Exp Pharmacol; 2018; 252():383-410. PubMed ID: 30367253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
    Carpenter JE; Murray BP; Dunkley C; Kazzi ZN; Gittinger MH
    Clin Toxicol (Phila); 2019 Apr; 57(4):282-286. PubMed ID: 30430874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Interactions With New Synthetic Opioids.
    Pérez-Mañá C; Papaseit E; Fonseca F; Farré A; Torrens M; Farré M
    Front Pharmacol; 2018; 9():1145. PubMed ID: 30364252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolomics predicts the pharmacological profile of new psychoactive substances.
    Olesti E; De Toma I; Ramaekers JG; Brunt TM; Carbó ML; Fernández-Avilés C; Robledo P; Farré M; Dierssen M; Pozo ÓJ; de la Torre R
    J Psychopharmacol; 2019 Mar; 33(3):347-354. PubMed ID: 30451567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran ("FLY") and benzodifuran ("DragonFLY") analogs.
    Halberstadt AL; Chatha M; Stratford A; Grill M; Brandt SD
    Neuropharmacology; 2019 Jan; 144():368-376. PubMed ID: 30385253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening of Novel Psychoactive Substances in Postmortem Matrices by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS).
    Fagiola M; Hahn T; Avella J
    J Anal Toxicol; 2018 Oct; 42(8):562-569. PubMed ID: 30371846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designer drugs: mechanism of action and adverse effects.
    Luethi D; Liechti ME
    Arch Toxicol; 2020 Apr; 94(4):1085-1133. PubMed ID: 32249347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designer drugs: a medicinal chemistry perspective (II).
    Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
    Ann N Y Acad Sci; 2021 Apr; 1489(1):48-77. PubMed ID: 32396701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
    Orsolini L; Corkery JM; Chiappini S; Guirguis A; Vento A; De Berardis D; Papanti D; Schifano F
    Curr Neuropharmacol; 2020; 18(9):809-837. PubMed ID: 31933443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knowledge and Use of Novel Psychoactive Substances in an Italian Sample with Substance Use Disorders.
    Dal Farra D; Valdesalici A; Zecchinato G; De Sandre A; Saccon D; Simonato P; Corazza O; Martinotti G; Smith AL; Solmi M
    Int J Environ Res Public Health; 2022 Jan; 19(2):. PubMed ID: 35055743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario.
    Arillotta D; Schifano F; Napoletano F; Zangani C; Gilgar L; Guirguis A; Corkery JM; Aguglia E; Vento A
    Front Neurosci; 2020; 14():149. PubMed ID: 32256304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Evolving Landscape of Designer Drugs.
    Kacinko SL; Papsun DM
    Methods Mol Biol; 2019; 1872():129-135. PubMed ID: 30350286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some new psychoactive substances: precursor chemicals and synthesis-driven end-products.
    Collins M
    Drug Test Anal; 2011; 3(7-8):404-16. PubMed ID: 21755608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic drugs of abuse.
    Tamama K
    Adv Clin Chem; 2021; 103():191-214. PubMed ID: 34229850
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.